| Symbol | CCCC |
|---|---|
| Name | C4 THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 490 ARSENAL WAY,SUITE 200, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | +1 617 231-0700 |
| Fax | — |
| — | |
| Website | https://www.c4therapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001662579 |
| Description | C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. Additional info from NASDAQ: |
📋 Mark Mossler (Officer) plans to sell 4K shares of C4 THERAPEUTICS, INC. (at $4.25 each, total $18K) Filed: Aug 14, 2026 | ID: 008193
Read more📋 JAY GELDMACHER (Ex-REZI CEO) plans to sell 83K shares of ADI GLOBAL DISTRIBUTION INC. (at $23.01 each, total $1.9M) Filed: Aug 14, 2026 | ID: 008190
Read moreNew Form SCHEDULE 13G/A - C4 Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000920 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G/A - C4 Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0002050709-26-000022 <b>Size:</b> 81 KB
Read more📋 Mark Mossler (Officer) plans to sell 20K shares of C4 THERAPEUTICS, INC. (at $3.93 each, total $77K) Filed: Aug 12, 2026 | ID: 008039
Read moreNew Form SCHEDULE 13G/A - C4 Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000895421-26-000231 <b>Size:</b> 13 KB
Read more(90% Positive) C4 THERAPEUTICS, INC. (CCCC) Announces Enrollment Update for results Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read moreDirector Anderson Kenneth Carl 🟢 acquired 2.6K shares of C4 Therapeutics, Inc. (CCCC) at $4.34 Transaction Date: Jul 01, 2026 | Filing ID: 000688
Read moreDirector GROGAN DONNA ROY 🟢 acquired 3.3K shares of C4 Therapeutics, Inc. (CCCC) at $4.34 Transaction Date: Jul 01, 2026 | Filing ID: 000689
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants… | Phase2 | Multiple Myeloma | Recruiting | 2026-02-18 | 2030-03-01 | ClinicalTrials.gov |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatam… | Phase1 | Multiple Myeloma (MM) | Recruiting | 2026-02-06 | 2029-06-01 | ClinicalTrials.gov |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of C… | Phase1 | Solid Tumors | Completed | 2022-12-08 | 2025-11-05 | ClinicalTrials.gov |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or… | Phase1 | Synovial Sarcoma | Terminated | 2022-03-25 | 2023-12-19 | ClinicalTrials.gov |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory N… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-04-27 | 2026-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Elranatamab | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cemsidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cemsidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| CFT8634 | Other | Phase PHASE1 | Synovial Sarcoma | TERMINATED | NCT05355753 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cemsidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cetuximab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Trametinib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT1946 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Dexamethasone Oral | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| cemsidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| Elranatamab | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Elranatamab | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Dexamethasone | DRUG | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Elranatamab | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | DRUG | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cetuximab | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Trametinib | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT1946 | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT8634 | DRUG | Phase PHASE1 | Synovial Sarcoma | TERMINATED | NCT05355753 |
| Dexamethasone Oral | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| cemsidomide | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |